Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.

Shares of Verve Therapeutics soared 75% Tuesday as Eli Lilly said it would acquire the gene-editing startup. The deal values Verve at about $1.3 billion, with some of Eli Lilly's potential ...

INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for ...

Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement, the ...

Shares of Beam Therapeutics (BEAM 0.30%) and Verve Therapeutics (VERV 81.34%) shot up 11% and 28%, respectively, on the day. On the downside, their counterparty in the deal, Eli Lilly ( LLY -1.99% ...

Eli Lilly to buy Verve Therapeutics for $10.50 per share, with total potential payout up to $13.50 per share. The $1.3 billion deal offers a 113% premium to Verve’s 30-day average stock price.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio. Verve’s innovative gene-editing technology, which permanently ...

On Tuesday, Eli Lilly And Co LLY agreed to acquire Verve Therapeutics, Inc. VERV , a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease .

Summary. Verve Therapeutics announced a partnership with Eli Lilly & Co., focusing on in-vivo gene editing technology, but investors remain concerned about the FDA's clinical hold on Verve's PCSK9 ...

INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for ...

Eli Lilly is taking a big swing into gene editing with a deal to buy Verve (NASDAQ:VERV) Therapeutics for up to $1.3 billion, paying $10.50 per share in cash plus a contingent right worth up to $3 ...